29 July 2006

Fish Oil: Latest research shows it is better than drugs

Positive research just keeps rolling in on fish oil. A pharmeceutical grade fish oil should be basic to everyone's nutritional plan. I use Dr. Sears fish oil as it consistently tests the best in my experiments.

Fish Oil Works Better Than Statins at Improving HDL Cholesterol
Dr. Joseph Mercola

A study has shown that fish oils are more effective than the statin drug Lipitor in positively affecting the levels of HDL ("good") cholesterol in obese and insulin-resistant men. HDL cholesterol protects against atherosclerosis by removing excess cholesterol from arterial cells, and low HDL levels can increase the risk of cardiovascular disease, particularly for those who are obese or insulin resistant.

In the six-week study, fish oils and Lipitor were given to 48 men, both separately and combined. Fish oil and Lipitor together greatly lowered plasma triacylglycerols and raised HDL cholesterol levels.

But only fish oil also influenced HDL cholesterol by altering the production and catabolism rates of HDL apolipoproteins (catabolism is the breakdown of complex molecules metabolically into simpler ones). Lipitor did not increase this effect when combined with the fish oils, and did not produce a similar effect on its own.

American Journal of Clinical Nutrition July 2006; 84(1): 37-43

18 July 2006

Resveratrol: It does more than extend your life!


Resveratrol increases both average and maximum lifespan across a vast range of organisms. The largest recorded percentage increases are shown here. [Adapted from Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nature Rev Drug Disc 2006 Jun;5(6):493-506.]

The evidence accumulating on resveratrol on life extension, cardiovascular and other positive effects is sufficient to recommend it as a regular supplement after Transfer Factor Plus and Dr. Sears Fish Oil. See Will Block. Resveratrol—Star Molecule Against Disease and Aging. Life Enhancement Foundation.

I've been taking this supplement for years and it may be one of the many factors that cause my biology age to be 24 years younger than my calendar age as tested by the Fronter Medical Clinic. I'm now recommending it to everyone.

15 July 2006

Linus Pauling Revisited: Latest on Vitamin C and Cancer

Vitamin C treatment shows cancer promise

By Sophia Maines

Lawrence Journal World, Monday, July 3, 2006

As Sandy Kellar battles ovarian cancer, she’s noticing an unusual vitality in herself that she doesn’t see in others with the disease.

“I can be a grandma and play with those grandkids in the backyard and anything I want,” the Overland Park resident said.

Kellar attributes her energy to her twice-weekly intravenous vitamin C treatments, a therapy that is gaining followers and spurring new research, including a trial at Kansas University Medical Center.

Jeanne Drisko, medical director for the KU Medical Center’s Program in Integrative Medicine, is in the process of completing a multiyear, $375,000 trial of intravenous vitamin C in ovarian cancer patients. The study is funded by the Cancer Treatment Research Foundation, a nonprofit agency based in Schaumburg, Ill.

The study began in 2002 and enrolled its last patient in 2005. Women in the trial were given doses of vitamin C intravenously twice a week while also undergoing conventional chemotherapy treatment. Drisko declined to discuss the results until the trial is complete, but she said the therapy is safe.

“We haven’t had any adverse events,” she said. “We’re encouraged enough that we’re continuing.”

Once championed by Nobel Laureate Linus Pauling, vitamin C as a cancer treatment suffered a setback in the 1970s when the Mayo Clinic studied orally ingested vitamin C pills and found no effect on cancer patients, Drisko said.

“Everyone thought, ‘This is the definitive study,’” she said of the Mayo Clinic’s research.

But vitamin C pills are different from intravenous vitamin C.

“When you give it by vein, it’s like a drug,” Drisko said. “When you give it by mouth, it’s just a vitamin.”

11 July 2006

Staying Alive: Cell-phone users as dangerous as drunks on the road

Watch out! You are more likely to get hit by a cell-phone user than a drunk driver.

A University of Utah study showed that motorists who talked on either handheld or hands-free phones:
  • drove slightly slower
  • were 9% slower to hit brakes
  • showed 24% more variation in following distance
  • 19% slower to resume normal speed after braking
  • more likely to crash
Watch your back. Three study participants rear-ended the pace car in the study!

Marginal drunks with a 0.08 blood-alcohol level:
  • drove more slowly yet more aggressively than either normal drivers or cell-phone users
  • followed more closely
  • twice as likely to brake 4 seconds before a collision would have occurred
  • hit their brakes with 23% more force
  • accident rates did not differ from normal drivers
The FAA provided $25K for the study and the Utah Highway Patrol provided devices for blood-alcohol measurement.

About 8% of drivers are talking on cell-phones which is much higher than the drunk driver rate. That means you are more likely to be injured by a cell-phone user than a drunk.

"We found that people are as impaired when they drive and talk on a cell phone as they are when they drive intoxicated at the legal blood-alcohol limit of 0.08 percent, which is the minimum level that defines illegal drunken driving in most U.S. states," says study co-author Frank Drews, an assistant professor of psychology. “If legislators really want to address driver distraction, then they should consider outlawing cell phone use while driving.”

A Comparison of the Cell Phone Driver and the Drunk Driver
David L. Strayer, Frank A. Drews, and Dennis J. Crouch
University of Utah, Salt Lake City, Utah
Human Factors: The Journal of the Human Factors and Ergonomics Society, Summer 2006

Flu Vaccine During Pregnancy: A Really Bad Idea


Influenza Vaccination During Pregnancy: A Critical Assessment of the Recommendations of the
Advisory Committee on Immunization Practices (ACIP)
David M. Ayoub, M.D. and F. Edward Yazbak, M.D
Journal of American Physicians and Surgeons 11:2, Summer 2006

Influenza vaccination during all trimesters of pregnancy is now universally recommended in the United States. We critically reviewed the influenza vaccination policy of the CDC's Advisory Committee on Immunization Practice (ACIP) and the citations that were used to support their recommendations.
The ACIP's citations and the current literature indicate that influenza infection is rarely a threat to a normal pregnancy. There is no convincing evidence of the effectiveness of influenza vaccination during this critical period. No studies have adequately assessed the risk of influenza vaccination during pregnancy, and animal safety testing is lacking. Thimerosal, a mercury-based preservative present in most inactivated formulations of the vaccine, has been implicated in human neurodevelopment disorders, including autism, and a broad range of animal and experimental reproductive toxicities including teratogenicity, mutagenicity, and fetal death. Thimerosal is classified as a human teratogen.
The ACIP policy recommendation of routinely administering influenza vaccine during pregnancy is ill-advised and unsupported by current scientific literature, and it should be withdrawn. Use of thimerosal during pregnancy should be contraindicated.

Vioxx - Even a little bit puts you at risk for cardiac events



Adverse Cardiovascular Effects of Rofecoxib
Steven E. Nissen, M.D., Cleveland Clinic Foundation
New England Journal of Medicine 355;2 - July 13, 2006

The recent public disclosure of data from a 12-month extension study of the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial provides new insights into the effect of rofecoxib on cardiovascular events. These new data reveal the full results of both the original study and the extension phase, including data tables and Kaplan–Meier curves. In the original article, the APPROVe investigators reported event rates using an unusual censoring rule in which events were excluded if they occurred more than 14 days after the study drug was stopped. All data in the new report are assessed by a conventional intention-to-treat analysis. This new report also provides analysis that uses several different end points, including the widely used end point of the Antiplatelet Trialists’ Collaboration (APTC) study. The original article included a post hoc hypothesis that curves for confirmed thrombotic events would not begin to diverge until after 18 months of exposure to rofecoxib. However, all intention-to-treat analyses in the newly released report show that the event curves begin to diverge much earlier, generally within four to six months.

07 July 2006

Frequencies for Tumor Cell Neosis

Neosis is a newly discovered mechanism involved in origin and growth of tumors. Up to 10% of tumor cells are polyploid cells and their role in cancer formation is not well understood. They can undergo neosis, giving rise to Raju cells which can manifest stem cell properties. Chemotherapy or radiation can cause tumor cells to go into senescence, then through neosis to form Raju cells that are resistant to treatment. This may be the mechanism for the origin and continued growth of tumor cells and explain why recurrence and resistance to treatment is a major problem.
See Rengaswami Rajaraman. A new type of cancer cell growth. The Scientist, June 2006, p 14.
Preliminary research indicates there is a frequency band for these cells in the 11mhz range that is common to all cancers. All individuals with cancer appear to test positive for these frequencies. Whether the frequencies help prevent tumor growth or recurrence remains needs to be tested by other researchers.
Always Improve Immune Function with Transfer Factor

Frequencies will stir up pathogens and help eliminate them. However, the immune system must do some of the work and prevent reinfection. Frequency applications are twice as effective when combined with Transfer Factor Plus Advanced Formula, typically two capsules twice a day when dealing with an infection, followed by two capsules once a day for maintenance.
Some individuals with autoimmune disease may not be able to tolerate Transfer Factor Plus. In that case, they should fall back to regular Transfer Factor in capsule form, or in RioVida juice form.
Dozens of immune supplements have been tested by the Frequency Research Foundation and none work as well as Transfer Factor Plus. It can be purchased at:
http://jeffsutherland.my4life.com
Order by phone by calling Dale Fawcett at (360) 598-6585.
Journal Articles

Cell Biol Int. 2005 Dec;29(12):1084-97. Epub 2005 Nov 28
Department of Medicine, Division of Hematology, Dalhousie University, Sir Charles Tupper Medical Building, 5850 College Street, Halifax, B3H 1X5 NS, Canada. r.rajaraman@dal.ca
We recently described a novel form of cell division termed neosis, which appears to be the mode of escape of cells from senescence and is involved in the neoplastic transformation and progression of tumors (Cancer Biol & Therap 2004;3:207-18). Neosis is a parasexual somatic reduction division and is characterized by (1) DNA damage-induced senescence/mitotic crisis and polyploidization, (2) followed by production of aneuploid daughter cells via nuclear budding, (3) asymmetric cytokinesis and cellularization conferring extended, but, limited mitotic life span to the offspring, and (4) is repeated several times during tumor growth. The immediate neotic progeny are termed the Raju cells, which seem to transiently display stem cell properties. The Raju cells immediately undergo symmetric mitotic division and become mature tumor cells. Exposure of tumor cells to genotoxic agents yields neosis-derived Raju cell progenies that are resistant to genotoxins, thus contributing to the recurrence of drug-resistant tumor growth. Similar events have been described in the literature under different names through several decades, but have been neglected due to the lack of appreciation of the significance of this process in cancer biology. Here we review and interpret the literature in the light of our observations and the recent advances in self-renewal in cancer. Neosis paradigm of self-renewal of cancer growth is consistent with the telomere attrition, aging and origin of cancer cells after reactivation of telomerase, and constitutes an alternative to the cancer stem cell hypothesis. We summarize the arguments favoring Raju cells and not cancer stem cells, as the source of self-renewal in cancer and present a comprehensive hypothesis of carcinogenesis, encompassing various aspects of cancer biology including senescence, tumor suppressor genes, oncogenes, cell cycle checkpoints, genomic instability, polyploidy and aneuploidy, natural selection, apoptosis, endoapoptosis, development of resistance to radiotherapy and chemotherapy leading tumor progression into malignancy.
Neosis: a novel type of cell division in cancer.
Sundaram M, Guernsey DL, Rajaraman MM, Rajaraman R.
Cancer Biol Ther. 2004 Feb;3(2):207-18. Epub 2004 Feb 1.Department of Medicine and Microbiology and Immunology, QEII Health Sciences Center, Faculty of Medicine, Dalhousie University, Halifax, Canada.

Using computerized video time-lapse microscopy, we studied early cellular events during carcinogen-induced transformation of C3H10T1/2 cells. Multinucleate/polyploid giant cells (MN/PGs) formed due to DNA damage are thought to die via mitotic catastrophe. Before they die, some MN/PGs undergo a novel type of cell division, termed neosis, characterized by karyokinesis via nuclear budding followed by asymmetric, intracellular cytokinesis, producing several small mononuclear cells, termed the Raju cells, with extended mitotic life span (MLS). Mitotic derivatives of Raju cells give rise to transformed cell lines, inherit genomic instability, display a phenotype and transcriptome different from the neosis mother cell, and anchorage-independent growth. Neosis of MN/PGs also precedes spontaneous transformation of p53-/- mouse cells. Rodent neotic clones, and primary and metastatic human tumor cells undergo spontaneous or induced secondary/tertiary neosis. Neosis seems to extend the MLS of cells under conditions of genetic duress not favoring mitosis. It precedes tumorigenesis, occurs several times during tumor progression, yielding tumor-initiating Raju cells and introducing tumor cell heterogeneity subject to natural selection during tumor progression. Events during neosis, and its relevance to origin of established cell lines, multistep carcinogenesis, cancer stem cells, and therapeutic advantages of anti-neotic agents (neosicides) are discussed.